09:04 AM EDT, 03/19/2026 (MT Newswires) -- GSK (GSK) said Thursday the US Food and Drug Administration has approved its experimental drug, Lynavoy, to treat cholestatic pruritus in adult patients with primary biliary cholangitis.
The company said the approval was based on a late-stage trial that showed the drug significantly reduced itching and related sleep disruption in patients compared with placebo.
Separately, GSK said its planned licensing deal with Alfasigma for the drug remains ongoing and subject to regulatory approvals.